A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Prior treatment

• Previously received tyrosine kinase 2 (TYK2) inhibitors
• Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects
• Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
• Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.

Other illness

• Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;
• Other conditions that the investigator deems unsuitable for participation in this study.
  • Other protocol defined inclusion/exclusion criteria could apply

Other

• Diagnosed with non-plaque psoriasis

• Male and female, ages 18 to 70 years
• Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
• Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
• Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.